Top

International Ophthalmology

Published in:

01-11-2020 | Retinal Detachment | Original Paper

Efficacy and safety of injecting increasing volumes into the extravascular spaces of the choroid using a blunt adjustable depth injector

Authors: Ifat Sher, Ettel Bubis, Hadas Ketter-Katz, Zehavit Goldberg, Rawan Saeed, Ygal Rotenstreich

Published in: International Ophthalmology | Issue 11/2020

Abstract

Purpose

To evaluate the efficacy and safety of injecting increasing volumes into the extravascular spaces of the choroid (EVSC) in rabbit eyes in vivo using a blunt adjustable depth injector.

Methods

Indocyanine green (ICG) was injected in the superior–temporal quadrant, 2 mm posterior to the limbus at increasing volumes (0.1–0.3 ml) into the EVSC of New Zealand rabbit eyes in vivo. Intraocular pressure (IOP) measurements, spectral domain optical coherence tomography (SD-OCT), fundus imaging and histology analysis were performed to assess the safety and efficacy of the injection.

Results

Volumes up to 0.3 ml were administered consistently. ICG injection was successfully monitored in vivo using infrared fundus imaging and SD-OCT. ICG was detected across the EVSC compartment, reaching the retinal pigment epithelium, optic nerve head and visual streak. Injection of 0.3 ml yielded maximal dye distribution with a coverage area of 61.8% ± 6.7% (mean ± standard error, SE) of the posterior segment. Maximal IOP elevation was recorded 5 min following injection of 0.2 and 0.3 ml ICG (+ 20.0 mmHg, + 19.4 mmHg, respectively). Twenty minutes post-injection, the IOP was < 15 mmHg in all injection volumes. No retinal detachment or hemorrhages were detected in any of the injected eyes.

Conclusions

This study demonstrates consistent and safe delivery of large volumes within the EVSC using a blunt adjustable depth injector that distributes the dye over 60% of the retinal surface. This injection system may offer a minimally invasive and easy way to deliver large volumes of pharmaceuticals into the posterior segment.

Available only for authorised users

Kang-Mieler JJ, Osswald CR, Mieler WF (2014) Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opin Drug Deliv 11:1647–1660CrossRef

Janoria KG, Gunda S, Boddu SH, Mitra AK (2007) Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4:371–388CrossRef

Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589–597. https://doi.org/10.1001/jamaophthalmol.2015.186CrossRefPubMedPubMedCentral

Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655CrossRefPubMed

Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930-4.e1. https://doi.org/10.1016/j.ajo.2008.07.007CrossRefPubMed

Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105–110. https://doi.org/10.1089/jop.2009.0076CrossRefPubMed

Karaca EE, Kepez Yldz B, Çubuk MÖ, Özdek Ş (2015) Epiretinal membranes in neovascular age-related macular degeneration: effect on outcomes of anti-vascular endothelial growth factor therapy. Retina (Philadelphia, Pa) 35:1540–1546. https://doi.org/10.1097/IAE.0000000000000531CrossRef

Rotenstreich Y, Tzameret A, Kalish SE et al (2017) A minimally invasive adjustable-depth blunt injector for delivery of pharmaceuticals into the posterior pole. Acta Ophthalmol 95:e197–e205. https://doi.org/10.1111/aos.13238CrossRefPubMed

Tzameret A, Sher I, Belkin M et al (2014) Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res 118:135–144. https://doi.org/10.1016/j.exer.2013.10.023CrossRefPubMed

10.

Tzameret A, Kalish SE, Sher I et al (2017) Long-term safety of transplanting human bone marrow stromal cells into the extravascular spaces of the choroid of rabbits. Stem Cells Int 2017:4061975. https://doi.org/10.1155/2017/4061975CrossRefPubMedPubMedCentral

11.

Pang CE, Mrejen S, Hoang QV et al (2015) Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina (Philadelphia, Pa) 35:1401–1406. https://doi.org/10.1097/IAE.0000000000000476CrossRef

12.

Chiang B, Kim YC, Edelhauser HF, Prausnitz MR (2016) Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries. Exp Eye Res 145:424–431. https://doi.org/10.1016/j.exer.2016.03.008CrossRefPubMedPubMedCentral

13.

Jung JH, Desit P, Prausnitz MR (2018) Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing. Invest Ophthalmol Vis Sci 59:2069–2079. https://doi.org/10.1167/iovs.17-23758CrossRefPubMedPubMedCentral

14.

Gu B, Liu J, Li X et al (2015) Real-time monitoring of suprachoroidal space (SCS) following SCS injection using ultra-high resolution optical coherence tomography in guinea pig eyes. Invest Ophthalmol Vis Sci 56:3623–3634. https://doi.org/10.1167/iovs.15-16597CrossRefPubMed

15.

Schwartz SD, Hubschman J-P, Heilwell G et al (2012) Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379:713–720. https://doi.org/10.1016/S0140-6736(12)60028-2CrossRefPubMed

16.

Boye SE, Boye SL, Lewin AS, Hauswirth WW (2013) A comprehensive review of retinal gene therapy. Mol Ther 21:509–519. https://doi.org/10.1038/mt.2012.280CrossRefPubMedPubMedCentral

17.

Schwartz SD, Regillo CD, Lam BL et al (2015) Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385:509–516. https://doi.org/10.1016/S0140-6736(14)61376-3CrossRefPubMed

18.

Rodrigues GA, Shalaev E, Karami TK et al (2018) Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res 36:29. https://doi.org/10.1007/s11095-018-2554-7CrossRefPubMedPubMedCentral

19.

Lu B, Malcuit C, Wang S et al (2009) Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 27:2126–2135. https://doi.org/10.1002/stem.149CrossRefPubMed

20.

Maguire AM, Simonelli F, Pierce EA et al (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240–2248. https://doi.org/10.1056/NEJMoa0802315CrossRefPubMedPubMedCentral

21.

Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS (2010) Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet 11:273–284. https://doi.org/10.1038/nrg2717CrossRefPubMed

22.

Nork TM, Murphy CJ, Kim CBY et al (2012) Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. Arch Ophthalmol 130:65–75. https://doi.org/10.1001/archophthalmol.2011.295CrossRefPubMed

23.

Weed L, Ammar MJ, Zhou S et al (2019) Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates. Mol Ther Methods Clin Dev 15:133–148. https://doi.org/10.1016/j.omtm.2019.08.011CrossRefPubMedPubMedCentral

24.

Jacobson SG, Cideciyan AV, Ratnakaram R et al (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130:9–24. https://doi.org/10.1001/archophthalmol.2011.298CrossRefPubMed

25.

Weleber RG, Pennesi ME, Wilson DJ et al (2016) Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology 123:1606–1620. https://doi.org/10.1016/j.ophtha.2016.03.003CrossRefPubMed

26.

Pennesi ME, Weleber RG, Yang P et al (2018) Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy. Hum Gene Ther 29:1428–1437. https://doi.org/10.1089/hum.2018.014CrossRefPubMed

27.

Hussain RM, Tran KD, Berrocal AM (2019) Subretinal injection of voretigene neparvovec-rzyl in a patient with RPE65-associated leber’s congenital amaurosis. OSLI 50:661–663CrossRef

28.

Lopez PF, Sippy BD, Lambert HM et al (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855–868PubMed

29.

Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Am J Ophthalmol 122:763. https://doi.org/10.1016/S0002-9394(14)70522-7CrossRef

30.

Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 26:859–870. https://doi.org/10.1097/01.iae.0000242842.14624.e7CrossRef

Title: Efficacy and safety of injecting increasing volumes into the extravascular spaces of the choroid using a blunt adjustable depth injector
Authors: Ifat Sher
Ettel Bubis
Hadas Ketter-Katz
Zehavit Goldberg
Rawan Saeed
Ygal Rotenstreich
Publication date: 01-11-2020
Publisher: Springer Netherlands
Keyword: Retinal Detachment
Published in: International Ophthalmology / Issue 11/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-020-01471-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy and safety of injecting increasing volumes into the extravascular spaces of the choroid using a blunt adjustable depth injector

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2020

Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study

Genetic variations in autoimmune genes and VKH disease

International globe and adnexal trauma epidemiology study (IGATES): a report from Central India on visual outcome in open globe injuries and correlation with ocular trauma score

Recent advances in the management of non-infectious posterior uveitis

Impact of the possible prognostic factors for visual outcomes of traumatic cataract surgery

Relationship between vascular densities of choriocapillaris and the whole choroid using OCTA